Trials / Completed
CompletedNCT02585180
Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia
Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia (VAP): an Ancillary Study of the DEMETER Trial (NCT02515617)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 420 (actual)
- Sponsor
- Centre Hospitalier Departemental Vendee · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Many studies provide evidence for the benefit of lower respiratory tract surveillance, mostly by culture of endotracheal secretions, to predict bacterial pathogens (especially multi-drugs resistant pathogens) involved in VAP. The DEMETER study (NCT02515617) assessing the medico-economical impact of the subglottic secretions drainage (SSD) provides the opportunity to evaluate the accuracy of the subglottic secretions culture surveillance to predict pathogens involved in VAP (in comparison with the concomitant endotracheal secretions surveillance). These subglottic and tracheal secretions culture surveillance will be masked to the investigators of the DEMETER Study. This ancillary study will be performed in 14 centers participating to the DEMETER study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Endotracheal tubes not allowing SSD | In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure |
| DEVICE | Endotracheal tubes allowing SSD | In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure. In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours. |
Timeline
- Start date
- 2015-11-04
- Primary completion
- 2017-11-29
- Completion
- 2017-11-29
- First posted
- 2015-10-23
- Last updated
- 2021-03-23
Locations
15 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT02585180. Inclusion in this directory is not an endorsement.